Boehringer Ingelheim and NascaCell announce research collaboration on aptamers
"We are delighted to work together with Boehringer's high-class research team", said Dr. Andreas Jenne, NascaCell's managing director. "Within our collaboration aptamers will be used to identify new druggable sites on protein targets. Our approach takes advantage of the unique properties of aptamers to specifically inactivate a particular functional epitope of a protein. Such aptamers may be subsequently used to discover novel small molecule lead compounds."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.